Compare Five9 Inc (FIVN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs BIO-TECHNE Corp — how do they compare? Five9 Inc trades at $35.1 (market cap $2.63B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 4.3× Five9 Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Five9 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and BIO-TECHNE Corp for 63 Days on average.
| FIVN | TECH | |
|---|---|---|
Market Cap | $2.63B | $11.36B |
Volume | 1,864,393 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $38.65 | $72.61 |
52-Week Low | $13.61 | $43.31 |
Typical Hold Time | 72 Days | 63 Days |
Enterprise Value | $2.78B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $33.78, up 1.47% today, with strong technical momentum and consistent earnings beats. Revenue growth accelerated to $1.15B in 2025, with net income turning positive at $39M. The stock shows bullish technical signals with support at $33 and resistance at $34, while AI revenue surged 78% in Q2 2026, driving investor optimism.
Outlook remains positive with 61% analyst buy ratings and $34 consensus target, though high P/E of 51.7 and insider selling pose risks. The company's shift to AI-driven contact center solutions positions it for growth, but competition and valuation concerns require monitoring.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
